In HIV-related Pneumocystis jirovecii pneumonia prophylaxis, what is the role of TMP-SMX and what common metabolic disturbances should be monitored?

• A. TMP-SMX is first-line for PCP prophylaxis; monitor for hyperkalemia and cytopenias; assess renal function.
• B. TMP-SMX is not used for PCP prophylaxis.
• C. TMP-SMX is used only for treatment, not prophylaxis.
• D. TMP-SMX causes hypokalemia.

Answer: (A)

TMP-SMX is the first-line option for preventing Pneumocystis jirovecii pneumonia in HIV patients with substantial risk, because it provides strong protection with well-established efficacy and tolerability for prophylaxis. When using this drug for prophylaxis, it’s important to watch for metabolic disturbances and kidney function. The trimethoprim component can impair potassium excretion in the kidneys, leading to hyperkalemia, so potassium levels should be monitored. It can also cause bone marrow suppression with cytopenias, so complete blood counts are useful to detect anemia, leukopenia, or thrombocytopenia. Since the medication is renally excreted and dosing may be affected by kidney function, assessing renal function is essential to ensure safe and effective prophylaxis and to adjust dosing if needed.